Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Inflammatory Disease Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IL-23 p19 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-23 p19 (IL23A) Recombinant Protein / IL-23 (p19/p40) Heterodimer HEK293 expressed, >95% purity, endotoxin <1 EU/ug. Sequence verified. |
View IL23A Products |
| Gene Delivery | IL-23 p19 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and expression validation. |
View IL23A Products |
| Benchmark Ab | Anti-IL-23 p19 Recombinant Antibody Sequence derived from Guselkumab/Risankizumab. Ideal positive control for binding assays. |
View IL23A Products |
| Validator | IL-23 p19 siRNA Set Target-specific knockdown pool for functional validation. |
View IL23A Products |
| Related Target A | IL-23R (IL-23 Receptor) Essential partner for receptor-binding inhibition assays and signaling studies. |
View IL23R Products |
| Related Target B | IL-12B (p40 subunit) Crucial for counter-screening to ensure p19 subunit specificity over IL-12. |
View IL12B Products |
| Related Target C | IL-12 (p35/p40) Heterodimer Critical for p40 counter-screening to ensure p19 specificity. |
View IL-12 Products |
| Related Target D | IL-17A Downstream effector cytokine in the Th17 pathway. |
View IL-17A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity screening against shared p40 subunit (IL-12) | High-purity IL-23 heterodimer and IL-12 heterodimer panels strictly verified by mass spectrometry. Homolog panels (IL-12) available for strict counter-screening. |
| High-affinity binding validation (SPR/BLI) | HEK293 expressed proteins preserving native glycosylation and conformational integrity. Cross-species orthologs (human, mouse, cynomolgus) available for PK/PD. |
| Lack of standardized controls | Sequence-verified clinical benchmark antibodies (Guselkumab/Risankizumab biosimilars) included. |
| Off-target assay noise / False positives | Endotoxin-controlled reagents (<1.0 EU/μg) to prevent non-specific immune cell activation. Validated siRNA included for precise specificity checks. |
Live IL-23 p19 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape targeting the IL-23 pathway has transitioned from dual IL-12/IL-23 inhibition (targeting the shared p40 subunit, e.g., Ustekinumab) to selective IL-23 p19 inhibition. This selectivity avoids the suppression of IL-12-mediated Th1 pathways, offering a superior safety profile and enhanced efficacy in moderate-to-severe plaque psoriasis, Crohn's disease, and ulcerative colitis. The race for IL-23 p19 therapeutics is intensifying, with major players (AbbVie, J&J, Eli Lilly) dominating the psoriasis space and rapidly expanding into Inflammatory Bowel Disease (IBD). As first-generation blockbusters reach maturity, the next wave of R&D is targeting oral peptide delivery (e.g., JNJ-2113 by Protagonist/J&J), bispecific antibodies addressing dual inflammatory pathways (e.g., IL-23/TNFα, IL-23/IL-17), and highly concentrated subcutaneous formulations for extended dosing intervals. Nanobody/VHH approaches (e.g., MoonLake Immunotherapeutics) also represent an emerging modality with potentially improved tissue penetration.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | AbbVie (Risankizumab), J&J (Guselkumab), Eli Lilly (Mirikizumab), Sun Pharma (Tildrakizumab) | Psoriasis, Crohn's Disease, Ulcerative Colitis | High-affinity binding assays (Need native glycosylated HEK293-expressed IL-23 p19). Counter-screening with IL-12 essential. |
| Oral Peptides / Small Molecules | J&J / Protagonist (JNJ-2113) | Plaque Psoriasis, IBD | Competitive binding assays (Need stable IL-23/IL-23R interaction screening tools and structural fidelity). |
| Bispecific / Multi-specifics | Boehringer Ingelheim, Sanofi, various early-stage | Psoriatic Arthritis, Refractory IBD | Simultaneous dual-target binding validation (Need cross-reactive IL-23 p19 and partner antigens, e.g., TNFα, IL-17A). |
| Nanobody / VHH | MoonLake Immunotherapeutics | Psoriatic Arthritis | Epitope mapping (Need specific truncated/mutant proteins for precise domain targeting). |
Molecular Differentiation & Assay Strategy
Developing best-in-class IL-23 p19 inhibitors requires rigorous differentiation in the following dimensions:
- Ultra-high affinity & slow off-rate (pM level) for extended dosing intervals (e.g., every 12 weeks). Assay: SPR/BLI with native IL-23 heterodimer.
- Strict subunit specificity (p19 vs p40) to avoid IL-12 pathway interference. Assay: Counter-screening ELISA/SPR using IL-12 (p35/p40) and free p40.
- Subcutaneous formulation stability at high concentrations (>100 mg/mL). Assay: High-concentration viscosity and aggregation tests (SEC-HPLC, DLS).
- Cross-species reactivity for NHP toxicology and mouse efficacy studies. Assay: Multi-species binding panel (human, cynomolgus, mouse IL-23).